EP3618856A1 - Immunothérapie anticancéreuse à base d'arnm à indications multiples - Google Patents
Immunothérapie anticancéreuse à base d'arnm à indications multiplesInfo
- Publication number
- EP3618856A1 EP3618856A1 EP18795120.7A EP18795120A EP3618856A1 EP 3618856 A1 EP3618856 A1 EP 3618856A1 EP 18795120 A EP18795120 A EP 18795120A EP 3618856 A1 EP3618856 A1 EP 3618856A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mrna
- seq
- dna
- emml
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108020004999 messenger RNA Proteins 0.000 title abstract 4
- 238000002619 cancer immunotherapy Methods 0.000 title description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 74
- 229960005486 vaccine Drugs 0.000 claims abstract description 46
- 201000011510 cancer Diseases 0.000 claims abstract description 34
- 238000000338 in vitro Methods 0.000 claims abstract description 27
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 14
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 12
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 12
- 230000002163 immunogen Effects 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 22
- 210000004881 tumor cell Anatomy 0.000 claims description 20
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 210000001165 lymph node Anatomy 0.000 claims description 8
- 229920002477 rna polymer Polymers 0.000 claims description 8
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 241000282465 Canis Species 0.000 claims description 3
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 3
- 229940030156 cell vaccine Drugs 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 230000003399 chemotactic effect Effects 0.000 claims description 2
- 230000009851 immunogenic response Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 238000011374 additional therapy Methods 0.000 claims 2
- 241000282324 Felis Species 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 19
- 108010077805 Bacterial Proteins Proteins 0.000 abstract description 7
- 230000028993 immune response Effects 0.000 abstract description 7
- 238000009566 cancer vaccine Methods 0.000 abstract description 6
- 229940022399 cancer vaccine Drugs 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 5
- 108020004414 DNA Proteins 0.000 description 116
- 102000053602 DNA Human genes 0.000 description 116
- 108090000623 proteins and genes Proteins 0.000 description 74
- 239000013612 plasmid Substances 0.000 description 69
- 102000004169 proteins and genes Human genes 0.000 description 59
- 230000014509 gene expression Effects 0.000 description 35
- 239000013598 vector Substances 0.000 description 33
- 108091026890 Coding region Proteins 0.000 description 32
- 238000004519 manufacturing process Methods 0.000 description 31
- 108091008146 restriction endonucleases Proteins 0.000 description 30
- 238000013461 design Methods 0.000 description 26
- 239000000499 gel Substances 0.000 description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 24
- 238000011282 treatment Methods 0.000 description 23
- 230000014616 translation Effects 0.000 description 22
- 238000013518 transcription Methods 0.000 description 20
- 230000035897 transcription Effects 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 108700021021 mRNA Vaccine Proteins 0.000 description 19
- 229940126582 mRNA vaccine Drugs 0.000 description 18
- 239000000427 antigen Substances 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 230000001413 cellular effect Effects 0.000 description 15
- 238000001890 transfection Methods 0.000 description 14
- 238000013519 translation Methods 0.000 description 14
- 108020004705 Codon Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 12
- 241000269368 Xenopus laevis Species 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000014621 translational initiation Effects 0.000 description 11
- 101710137500 T7 RNA polymerase Proteins 0.000 description 10
- -1 adenosine monophosphates Chemical class 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000009169 immunotherapy Methods 0.000 description 10
- 229930027917 kanamycin Natural products 0.000 description 10
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 10
- 229960000318 kanamycin Drugs 0.000 description 10
- 229930182823 kanamycin A Natural products 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 125000002652 ribonucleotide group Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 108091028664 Ribonucleotide Proteins 0.000 description 8
- 108091023045 Untranslated Region Proteins 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000000805 cytoplasm Anatomy 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000002336 ribonucleotide Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 108020005345 3' Untranslated Regions Proteins 0.000 description 7
- 108020003589 5' Untranslated Regions Proteins 0.000 description 7
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000013599 cloning vector Substances 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 210000000633 nuclear envelope Anatomy 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 6
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 6
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 6
- 239000006137 Luria-Bertani broth Substances 0.000 description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 6
- 229960005305 adenosine Drugs 0.000 description 6
- 230000005975 antitumor immune response Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241000180579 Arca Species 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 108091036407 Polyadenylation Proteins 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 108010006785 Taq Polymerase Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 229920002988 biodegradable polymer Polymers 0.000 description 5
- 239000004621 biodegradable polymer Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000000172 cytosol Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000004055 small Interfering RNA Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 102000007327 Protamines Human genes 0.000 description 4
- 108010007568 Protamines Proteins 0.000 description 4
- 108091036066 Three prime untranslated region Proteins 0.000 description 4
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 4
- 229960003669 carbenicillin Drugs 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 229940029575 guanosine Drugs 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229940048914 protamine Drugs 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 238000007399 DNA isolation Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000010310 bacterial transformation Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 229940126546 immune checkpoint molecule Drugs 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 2
- BGTXMQUSDNMLDW-AEHJODJJSA-N 2-amino-9-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F BGTXMQUSDNMLDW-AEHJODJJSA-N 0.000 description 2
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 2
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 2
- 102100030157 Microphthalmia-associated transcription factor Human genes 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 2
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- KHYOUGAATNYCAZ-XVFCMESISA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=S)NC(=O)C=C1 KHYOUGAATNYCAZ-XVFCMESISA-N 0.000 description 2
- YIJVOACVHQZMKI-JXOAFFINSA-N [[(2r,3s,4r,5r)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 YIJVOACVHQZMKI-JXOAFFINSA-N 0.000 description 2
- VEWJOCYCKIZKKV-GBNDHIKLSA-N [[(2r,3s,4r,5s)-5-(2,4-dioxo-1h-pyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1C1=CNC(=O)NC1=O VEWJOCYCKIZKKV-GBNDHIKLSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000008206 lipophilic material Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- PYNVSZMFFVWFQA-NOMGDLSISA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(1-hydroxyethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound O[C@@H]1[C@H](O)[C@@H](C(O)C)O[C@H]1N1C(NC(N)=NC2=O)=C2N=C1 PYNVSZMFFVWFQA-NOMGDLSISA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101000896234 Homo sapiens Baculoviral IAP repeat-containing protein 5 Proteins 0.000 description 1
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108700015301 Streptococcus pyogenes Emm55 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- ZKVLEFBKBNUQHK-UHFFFAOYSA-N helium;molecular nitrogen;molecular oxygen Chemical compound [He].N#N.O=O ZKVLEFBKBNUQHK-UHFFFAOYSA-N 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229940032219 immunotherapy vaccine Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229940035824 lymphoma vaccine Drugs 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229940038694 mRNA-based vaccine Drugs 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940034080 provenge Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/583,599 US10682401B2 (en) | 2015-05-19 | 2017-05-01 | Multi-indication mRNA cancer immunotherapy |
PCT/US2018/030142 WO2018204234A1 (fr) | 2017-05-01 | 2018-04-30 | Immunothérapie anticancéreuse à base d'arnm à indications multiples |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3618856A1 true EP3618856A1 (fr) | 2020-03-11 |
EP3618856A4 EP3618856A4 (fr) | 2021-02-24 |
Family
ID=64016702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18795120.7A Withdrawn EP3618856A4 (fr) | 2017-05-01 | 2018-04-30 | Immunothérapie anticancéreuse à base d'arnm à indications multiples |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3618856A4 (fr) |
WO (1) | WO2018204234A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3125532A1 (fr) * | 2019-01-04 | 2020-07-09 | Etherna Immunotherapies Nv | Vaccins a arnm |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7795020B2 (en) * | 1998-01-14 | 2010-09-14 | Morphogenesis, Inc. | Tumor cell vaccines |
US7348015B2 (en) * | 1998-01-14 | 2008-03-25 | Morphogenesis, Inc. | Antigen modified cancer cell vaccines for cancer therapy |
WO2015134577A1 (fr) * | 2014-03-06 | 2015-09-11 | Morphogenesis, Inc. | Vecteur adn et vaccins à cellules tumorales transformées |
ES2875589T3 (es) * | 2015-05-15 | 2021-11-10 | Curevac Ag | Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm |
DK3297664T3 (da) * | 2015-05-19 | 2020-12-07 | Morphogenesis Inc | Cancervaccine omfattende mrna, der koder for et m-lignende protein |
-
2018
- 2018-04-30 WO PCT/US2018/030142 patent/WO2018204234A1/fr unknown
- 2018-04-30 EP EP18795120.7A patent/EP3618856A4/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP3618856A4 (fr) | 2021-02-24 |
WO2018204234A1 (fr) | 2018-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016264363B2 (en) | Cancer vaccine comprising mRNA encoding a M-like-protein | |
US10682401B2 (en) | Multi-indication mRNA cancer immunotherapy | |
Wang et al. | mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma | |
KR102378404B1 (ko) | 단일가닥 rna 제공 방법 | |
CN105849269B (zh) | Rna转录载体及其用途 | |
US20160235787A1 (en) | Epitope Spreading Associated with CAR T-Cells | |
JP2018521115A5 (fr) | ||
CN116322716A (zh) | Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性 | |
US20230226094A1 (en) | Click-modified mrna | |
WO2021197391A1 (fr) | Procédé de préparation d'une cellule immunitaire modifiée | |
CA3140496A1 (fr) | Arn therapeutique contre le cancer de l'ovaire | |
EP3618856A1 (fr) | Immunothérapie anticancéreuse à base d'arnm à indications multiples | |
CN105924531B (zh) | 一种抗il-4r单链抗体与蜂毒肽融合蛋白及其应用 | |
US20200317764A1 (en) | Modified mrna for multicell transformation | |
US20230270860A1 (en) | Modified mrna for multicell transformation | |
EP3502258A1 (fr) | Arnm transcrit in vitro modifié en un clic pour l'expression génique | |
CA3178223A1 (fr) | Arnm modifie pour transformation multicellulaire | |
CN114729021A (zh) | 能破坏细胞的氨基酸序列及相关核苷酸序列和相关的应用 | |
WO2024059791A1 (fr) | Grandes recombinases de sérine, systèmes et utilisations de celles-ci | |
JP2003500037A (ja) | エピトープタンパク質のタグをもつ転移因子 | |
WO2024097894A1 (fr) | Compositions et procédés de vaccins à base d'acide ribonucléique codant nye-so-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191115 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LAWMAN, MICHAEL, J. P. Inventor name: RAMIYA, VIJAY Inventor name: SHAMBLOTT, MICHAEL, J. Inventor name: LAWMAN, PATRICIA, D. Inventor name: BASTAWROUS, MARINA VICTOR, ABDELMASEEH Inventor name: GENTILINI, MEGHAN |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40017003 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210126 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07H 21/02 20060101ALI20210120BHEP Ipc: A61P 35/00 20060101ALI20210120BHEP Ipc: A61K 39/00 20060101AFI20210120BHEP Ipc: A61K 39/02 20060101ALI20210120BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220112 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20220524 |